ResearcherSecond Affiliated Hospital of Kunming Medical CollegeActive in the last 2 years

Hong Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4866-6683; OpenAlex author ID A5103200755. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration. Last author DOI 10.1186/s12885-025-13567-5 ↗
RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-022-02490-3 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Youlong Zhu · 1 shared paper, 2025 · strength 0.26
- Paper NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration. DOI 10.1186/s12885-025-13567-5 ↗
Qiu Tu · 1 shared paper, 2022 · strength 0.13
- Paper RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic… DOI 10.1186/s13046-022-02490-3 ↗
Bo Zhao · 1 shared paper, 2022 · strength 0.13
- Paper RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic… DOI 10.1186/s13046-022-02490-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.